Clinical Trial Update: Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating metronomic capecitabine with or without a PD-1 antibody as adjuvant therapy for high-risk nasopharyngeal carcinoma; currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING